Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.53 |
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.39 |
| ▸ | PLK4 | O00444 | 2/20 | 0.39 |
| ▸ | AURKA | O14965 | 2/20 | 0.39 |
| ▸ | ABL1 | P00519 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5792208 | 1.00 | ALDH1A1 (0.54) | ALDH1A1LMNATSHRNPSR1HTT | |
| SCHEMBL5788095 | 0.87 | HRH4 (0.53) | ALDH1A1LMNATSHRNPSR1HTT | |
| SCHEMBL5788097 | 0.87 | HRH4 (0.53) | ALDH1A1LMNATSHRNPSR1HTT | |
| SCHEMBL5788367 | 0.82 | PDE10A (0.57) | ALDH1A1LMNATSHRNPSR1HTT | |
| SCHEMBL5788363 | 0.82 | PDE10A (0.57) | ALDH1A1LMNATSHRNPSR1HTT | |
| SCHEMBL5791619 | 0.81 | PDE10A (0.54) | ALDH1A1LMNANPSR1HTTPDE10A | |
| SCHEMBL5789458 | 0.81 | PDE10A (0.54) | ALDH1A1LMNATSHRNPSR1HTT | |
| SCHEMBL5789461 | 0.81 | PDE10A (0.54) | ALDH1A1LMNATSHRNPSR1HTT | |
| SCHEMBL5791021 | 0.81 | PDE10A (0.54) | ALDH1A1LMNATSHRNPSR1HTT | |
| SCHEMBL5791016 | 0.81 | PDE10A (0.54) | ALDH1A1LMNATSHRNPSR1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6657060-B2 | Neuropeptide Y antagonists; treatment of eating disorders such as obesity and hyperphagia | HOFFMAN-LA ROCHE INC. | 2003-12-02 | — | — | US | claimed |
| US-20020086858-A1 | Pyrimidine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-04 | — | — | US | claimed |
| EP-1335906-B1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 2006-09-27 | — | — | EP | disclosed |
| US-6657060-B2 | Neuropeptide Y antagonists; treatment of eating disorders such as obesity and hyperphagia | HOFFMAN-LA ROCHE INC. | 2003-12-02 | — | — | US | disclosed |
| EP-1335906-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y RECEPTOR LIGANDS | F. Hoffman-la Roche AG (CH) | 2003-08-20 | — | — | EP | disclosed |
| US-20020086858-A1 | Pyrimidine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-04 | — | — | US | disclosed |
| WO-2002038551-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y RECEPTOR LIGANDS | F. HOFFMAN-LA ROCHE AG (CH) | 2002-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086858-A1 | Pyrimidine derivatives | NPY1R, NPY5R, NPY4R | ALDH1A1 4142/4885LMNA 4277/4885TSHR 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.